Stay updated on Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page.

Latest updates to the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page
- Check5 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3 on the page; this reflects a backend/UI update and does not modify study data or content.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedRevision: v3.4.2 was added to the page, and the funding-status notice and Revision: v3.4.1 were removed.SummaryDifference0.4%

- Check41 days agoChange DetectedA site-wide notice about a lapse in government funding affecting updates was added, and the page revision tag was updated from v3.4.0 to v3.4.1, to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check48 days agoChange DetectedAdditions include showing glossary and revision/version labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0); Deletions remove the previous lowercase QC label (Last Update Submitted that met QC Criteria), No FEAR Act data, and an older revision stamp (Revision: v3.3.4). These are minor metadata/label changes and do not affect core study content such as results, eligibility criteria, or key dates; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no substantive changes to the study details are visible.SummaryDifference0.0%

- Check84 days agoChange DetectedLocations section now lists District of Columbia and New Jersey as study sites. The revision label is updated to Revision: v3.3.3.SummaryDifference0.3%

Stay in the know with updates to Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page.